Drugs / Iparomlimab/Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07007728 | Jun 2025 → Dec 2026 expected | metastasis from malignant tumor of colon | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab/Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07007728 ↗ |